Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Capital Expenditures (2020 - 2025)

Benitec Biopharma (BNTC) has disclosed Capital Expenditures for 5 consecutive years, with $6000.0 as the latest value for Q1 2025.

  • Quarterly Capital Expenditures changed N/A to $6000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Jun 2025, down 50.0% year-over-year, with the annual reading at $18000.0 for FY2025, 89.94% down from the prior year.
  • Capital Expenditures hit $6000.0 in Q1 2025 for Benitec Biopharma, up from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $15000.0 in Q1 2021 to a low of -$141000.0 in Q2 2021.
  • Historically, Capital Expenditures has averaged -$21200.0 across 4 years, with a median of $6000.0 in 2025.
  • Biggest five-year swings in Capital Expenditures: tumbled 1184.62% in 2021 and later soared 109.22% in 2022.
  • Year by year, Capital Expenditures stood at -$141000.0 in 2021, then skyrocketed by 109.22% to $13000.0 in 2022, then plummeted by 92.31% to $1000.0 in 2023, then soared by 500.0% to $6000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BNTC at $6000.0 in Q1 2025, $1000.0 in Q2 2023, and $13000.0 in Q2 2022.